MCID: OVR044
MIFTS: 36

Ovarian Carcinosarcoma

Categories: Rare diseases, Cancer diseases, Reproductive diseases

Aliases & Classifications for Ovarian Carcinosarcoma

MalaCards integrated aliases for Ovarian Carcinosarcoma:

Name: Ovarian Carcinosarcoma 12 49 55 14
Ovarian Malignant Mixed Epithelial Mesenchymal Tumor 49 55
Malignant Mixed Müllerian Tumor of the Ovary 49 55
Ovarian Malignant Mixed Müllerian Tumor 49 55
Mmmt of the Ovary 49 55
Malignant Mixed Mullerian Tumor of the Ovary 49
Ovarian Malignant Mesodermal Mixed Tumor 12
Ovarian Malignant Mixed Mullerian Tumor 12
Carcinosarcoma of Ovary 69
Ovarian Mmmt 12

Characteristics:

Orphanet epidemiological data:

55

Classifications:



External Ids:

Disease Ontology 12 DOID:6170
NCIt 46 C9192
SNOMED-CT 64 702368000
Orphanet 55 ORPHA213512
UMLS via Orphanet 70 C0392998
ICD10 via Orphanet 33 C56
UMLS 69 C0392998

Summaries for Ovarian Carcinosarcoma

NIH Rare Diseases : 49 Ovarian carcinosarcoma, also known as a malignant mixed mullerian tumor (MMMT) of the ovary, is a rare, aggressive cancer of the ovary with characteristics of two types of cancer: carcinoma and sarcoma. Because women with this cancer often have no symptoms, more than half of women are diagnosed at an advanced stage. When present, symptoms may include pain in the abdomen or pelvic area, bloating or swelling of the abdomen, quickly feeling full when eating, or other digestive problems. The cause of ovarian carcinosarcoma is not yet understood. Treatment usually consists of surgery to remove the tumor and chemotherapy. The chance of recovery and long-term survival (prognosis) is poor, with a reported 5-year survival rate of about 28%. Last updated: 10/18/2017

MalaCards based summary : Ovarian Carcinosarcoma, also known as ovarian malignant mixed epithelial mesenchymal tumor, is related to cystic teratoma and teratoma. An important gene associated with Ovarian Carcinosarcoma is TUBB3 (Tubulin Beta 3 Class III), and among its related pathways/superpathways is Neuroscience. The drugs Carboplatin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include ovary, liver and brain.

Related Diseases for Ovarian Carcinosarcoma

Diseases related to Ovarian Carcinosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 116)
# Related Disease Score Top Affiliating Genes
1 cystic teratoma 29.7 ENO2 SYP
2 teratoma 29.6 ENO2 SYP
3 malignant mixed mullerian tumor 10.3
4 chondroid chordoma 10.2 ENO2 TUBB3
5 lymphoepithelioma-like carcinoma 10.2 CD274 ENO2
6 malignant sertoli cell tumor 10.1 ENO2 SYP
7 urinary bladder small cell neuroendocrine carcinoma 10.1 ENO2 SYP
8 sinonasal undifferentiated carcinoma 10.1 ENO2 SYP
9 auditory system cancer 10.1 ENO2 SYP
10 cutaneous ganglioneuroma 10.1 ENO2 SYP
11 sensory organ benign neoplasm 10.1 ENO2 SYP
12 middle ear adenoma 10.1 ENO2 SYP
13 gallbladder small cell carcinoma 10.1 ENO2 SYP
14 pancreatic somatostatinoma 10.1 ENO2 SYP
15 extrahepatic bile duct adenocarcinoma 10.1 ENO2 SYP
16 small cell carcinoma of the bladder 10.1 ENO2 SYP
17 papillary tumor of the pineal region 10.1 ENO2 SYP
18 orbital cancer 10.1 ENO2 SYP
19 pulmonary large cell neuroendocrine carcinoma 10.1 ENO2 SYP
20 atypical follicular adenoma 10.1 ENO2 SYP
21 central nervous system primitive neuroectodermal neoplasm 10.1 ENO2 SYP
22 cerebellum cancer 10.1 ENO2 SYP
23 subependymal glioma 10.1 ENO2 SYP
24 cerebral neuroblastoma 10.1 ENO2 SYP
25 cauda equina neoplasm 10.1 ENO2 SYP
26 extraosseous chondrosarcoma 10.1 ENO2 SYP
27 benign ependymoma 10.1 ENO2 SYP
28 malignant teratoma 10.1 ENO2 SYP
29 astroblastoma 10.1 ENO2 SYP
30 cerebral ventricle cancer 10.1 ENO2 SYP
31 cerebrum cancer 10.1 ENO2 SYP
32 endometrial small cell carcinoma 10.1 ENO2 SYP
33 melanotic neuroectodermal tumor 10.1 ENO2 SYP
34 subependymoma 10.1 ENO2 SYP
35 supratentorial cancer 10.1 ENO2 SYP
36 mucinous ovarian cystadenoma 10.1 ENO2 SYP
37 angiomyoma 10.1 ENO2 SYP
38 gastric squamous cell carcinoma 10.1 ENO2 SYP
39 gastric small cell carcinoma 10.1 ENO2 SYP
40 small cell neuroendocrine carcinoma 10.1 ENO2 SYP
41 bone benign neoplasm 10.1 ENO2 SYP
42 meningeal melanomatosis 10.1 ENO2 SYP
43 carcinoid tumors, intestinal 10.1 ENO2 SYP
44 cervical clear cell adenocarcinoma 10.1 ENO2 SYP
45 papillary ependymoma 10.1 ENO2 SYP
46 extraskeletal ewing sarcoma 10.1 ENO2 SYP
47 connective tissue benign neoplasm 10.1 ENO2 SYP
48 glomus tumor 10.1 ENO2 SYP
49 intraocular retinoblastoma 10.1 ENO2 SYP
50 sclerosing hemangioma 10.1 ENO2 SYP

Graphical network of the top 20 diseases related to Ovarian Carcinosarcoma:



Diseases related to Ovarian Carcinosarcoma

Symptoms & Phenotypes for Ovarian Carcinosarcoma

Drugs & Therapeutics for Ovarian Carcinosarcoma

Drugs for Ovarian Carcinosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 54)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
2
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
3
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
4
Ifosfamide Approved Phase 3 3778-73-2 3690
5
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
6
Cyproheptadine Approved Phase 3 129-03-3 2913
7
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
8 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
9 Antimitotic Agents Phase 3,Phase 2,Phase 1
10 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
11 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
12 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
13 Alkylating Agents Phase 3,Phase 2
14 Isophosphamide mustard Phase 3 0
15 Anti-Allergic Agents Phase 3
16 Antipruritics Phase 3
17 Dermatologic Agents Phase 3
18 Gastrointestinal Agents Phase 3
19 Histamine Antagonists Phase 3
20 Histamine H1 Antagonists Phase 3
21
Histamine Phosphate Phase 3 51-74-1 65513
22 Neurotransmitter Agents Phase 3
23
Serotonin Phase 3 50-67-9 5202
24 Serotonin Agents Phase 3
25 Serotonin Antagonists Phase 3
26
Gemcitabine Approved Phase 2 95058-81-4 60750
27
Cisplatin Approved Phase 2,Phase 1 15663-27-1 2767 441203 84093
28
Doxorubicin Approved, Investigational Phase 2,Phase 1 23214-92-8 31703
29
Everolimus Approved Phase 2 159351-69-6 6442177
30
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
31
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 6436030 5284616
32
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
33
Doxil Approved June 1999 Phase 2,Phase 1 31703
34 Anti-Infective Agents Phase 2
35 Antimetabolites Phase 2
36 Antimetabolites, Antineoplastic Phase 2
37 Antiviral Agents Phase 2
38 Immunosuppressive Agents Phase 2
39 Anti-Bacterial Agents Phase 2,Phase 1
40 Antibiotics, Antitubercular Phase 2,Phase 1
41 Topoisomerase Inhibitors Phase 2,Phase 1
42 Endothelial Growth Factors Phase 2,Phase 1
43 Mitogens Phase 2,Phase 1
44 Antibodies Phase 2,Phase 1
45 Antibodies, Monoclonal Phase 2,Phase 1
46 Antifungal Agents Phase 2
47 Immunoglobulins Phase 2,Phase 1
48 Liver Extracts Phase 2
49
Lenograstim Approved, Investigational Phase 1 135968-09-1
50
Docetaxel Approved May 1996, Investigational Phase 1 114977-28-5 148124 9877265

Interventional clinical trials:

(show all 21)

# Name Status NCT ID Phase Drugs
1 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
2 Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Active, not recruiting NCT00954174 Phase 3 Carboplatin;Ifosfamide;Paclitaxel
3 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
4 Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Unknown status NCT00838656 Phase 2 carboplatin;gemcitabine hydrochloride;paclitaxel
5 Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer Completed NCT00511992 Phase 2 Avastin;Paclitaxel;Cisplatin
6 Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors Completed NCT00815945 Phase 2 PegLiposomal Doxorubicin;Carboplatin
7 Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma Completed NCT00390234 Phase 2 ziv-aflibercept
8 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
9 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2 BI 2536
10 Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract Completed NCT00003334 Phase 2 paclitaxel;pegylated liposomal doxorubicin hydrochloride
11 Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer Completed NCT00032162 Phase 1, Phase 2 carboplatin;pegylated liposomal doxorubicin hydrochloride
12 Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Recruiting NCT02101775 Phase 2 Gemcitabine Hydrochloride;WEE1 Inhibitor AZD1775
13 Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)_MITO 26 Not yet recruiting NCT02993705 Phase 2 Trabectedin
14 Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) Completed NCT00085358 Phase 1 carboplatin;paclitaxel;docetaxel
15 Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer Completed NCT00352300 Phase 1 Carboplatin;Paclitaxel
16 Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors Completed NCT00066651 Phase 1
17 Immunotoxin Therapy in Treating Patients With Advanced Cancer Completed NCT00006981 Phase 1
18 Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT00989651 Phase 1 Carboplatin;Cisplatin;Paclitaxel;Veliparib
19 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers Suspended NCT02020707 Phase 1 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
20 Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial Completed NCT00904514
21 Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy Active, not recruiting NCT01080521

Search NIH Clinical Center for Ovarian Carcinosarcoma

Genetic Tests for Ovarian Carcinosarcoma

Anatomical Context for Ovarian Carcinosarcoma

MalaCards organs/tissues related to Ovarian Carcinosarcoma:

38
Ovary, Liver, Brain, Endothelial, Small Intestine

Publications for Ovarian Carcinosarcoma

Articles related to Ovarian Carcinosarcoma:

(show all 44)
# Title Authors Year
1
Comparison of first-line chemotherapy regimens for ovarian carcinosarcoma: a single institution case series and review of the literature. ( 29426293 )
2018
2
Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study. ( 27958685 )
2017
3
SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression. ( 28679774 )
2017
4
Prognostic assessment of sarcomatous histologic subtypes of ovarian carcinosarcoma. ( 28791266 )
2017
5
Paraneoplastic cerebellar degeneration secondary to ovarian carcinosarcoma: a cerebellar conundrum. ( 28790096 )
2017
6
Clinical Significance of Programmed Death Liganda891 and Intra-Tumoral CD8+ T Lymphocytes in Ovarian Carcinosarcoma. ( 28125702 )
2017
7
Ovarian Carcinosarcoma and Its Association with Mature Cystic Teratoma and Primary Tubal Carcinoma. ( 27807494 )
2016
8
Patterns of care, predictors and outcomes of chemotherapy for ovarian carcinosarcoma: A National Cancer Database analysis. ( 27107722 )
2016
9
Mature Teratoma Associated with Bilateral Ovarian Carcinosarcoma - Accidental Association or Etiopathogenetic Determinism? - Case Report. ( 27819640 )
2016
10
Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTEAr), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro. ( 26474755 )
2015
11
Ovarian carcinosarcoma: a case report, diagnosis, treatment and literature review. ( 27418786 )
2015
12
Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft. ( 25962155 )
2015
13
Presence of both Mesenchymal and Carcinomatous Features in an In-vitro Model of Ovarian Carcinosarcoma Derived from Patients' Ascitic Fluid. ( 25802693 )
2015
14
A rare case of ovarian carcinosarcoma with neuroendocrine differentiation. ( 24971408 )
2014
15
Radical surgical cytoreduction in the treatment of ovarian carcinosarcoma. ( 24631447 )
2014
16
Rhabdomyosarcoma with pseudolipoblasts arising in ovarian carcinosarcoma: a distinctive postchemotherapy morphologic variant mimicking pleomorphic liposarcoma. ( 24587930 )
2014
17
Ovarian carcinosarcoma in a renal transplant recipient. A unique case of a rare tumor. ( 26052208 )
2014
18
Gynecologic Cancer InterGroup (GCIG) Consensus Review for Uterine and Ovarian Carcinosarcoma. ( 25341582 )
2014
19
Prognostic determinants in patients with uterine and ovarian carcinosarcoma. ( 23947079 )
2013
20
Ovarian carcinosarcoma: effects of cytoreductive status and platinum-based chemotherapy on survival. ( 23781249 )
2013
21
Large polyp of the small intestine: an unexpected metastasis of ovarian carcinosarcoma. ( 23926191 )
2013
22
Chemotherapy and/or radiotherapy in combination with surgery for ovarian carcinosarcoma. ( 23450567 )
2013
23
Ovarian carcinosarcoma associated with bilateral tubal intraepithelial carcinoma: a case report. ( 23722511 )
2013
24
Complete response with pegylated liposomal doxorubicin as a second-line therapy in metastatic ovarian carcinosarcoma: Significance of assessment of the response by FDG-PET. ( 24371621 )
2012
25
Differential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcoma cell lines is linked to tubulin-beta-III expression. ( 22209775 )
2012
26
Solitary splenic metastasis from ovarian carcinosarcoma: a case report. ( 21310035 )
2011
27
Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody. ( 22075385 )
2011
28
Malignant melanoma arising in an ovarian carcinosarcoma: case report and review of the literature. ( 21293284 )
2011
29
Whole-body FDG PET/CT in diagnosis of internal mammary nodal metastasis of ovarian carcinosarcoma. ( 21552025 )
2011
30
A rare case of ovarian carcinosarcoma successfully treated with the neoadjuvant chemotherapy of paclitaxel and ifosfamide. ( 21417665 )
2011
31
Platinum, anthracycline, and alkylating agent-based chemotherapy for ovarian carcinosarcoma. ( 19820383 )
2009
32
Angiogenesis and expression of angiogenic agents in uterine and ovarian carcinosarcomas. ( 18321361 )
2008
33
Current management of ovarian carcinosarcoma. ( 17362309 )
2007
34
A case of primary ovarian carcinosarcoma and vulvar carcinoma with widespread lymphadenopathy. ( 16846899 )
2006
35
Complete cytoreduction combined with early postoperative intraperitoneal chemotherapy for ovarian carcinosarcoma. Report of two cases. ( 16645301 )
2006
36
Clinical features and outcomes of uterine and ovarian carcinosarcoma. ( 16271748 )
2006
37
Clinicopathological features of ovarian carcinosarcomas: a single institution experience. ( 15589592 )
2005
38
Primary ovarian carcinosarcoma: a case report and review of the literature. ( 15493190 )
2004
39
Transition of epithelial toward mesenchymal differentiation during ovarian carcinosarcoma tumorigenesis. ( 12893202 )
2003
40
Unusual Trousseau's syndrome in ovarian carcinosarcoma: multiple systemic thromboembolic events. ( 12554280 )
2002
41
Ovarian carcinosarcoma [correction of carcinoma]. ( 11418412 )
2001
42
Borderline serous cystadenocarcinoma with coexistent angiosarcoma: an unusual form of ovarian carcinosarcoma. ( 12574850 )
2001
43
Prognostic factors in ovarian carcinosarcoma: a clinicopathological and immunohistochemical analysis of 23 cases. ( 11119124 )
2000
44
MR images of ovarian carcinosarcoma. ( 10646984 )
1999

Variations for Ovarian Carcinosarcoma

Expression for Ovarian Carcinosarcoma

Search GEO for disease gene expression data for Ovarian Carcinosarcoma.

Pathways for Ovarian Carcinosarcoma

Pathways related to Ovarian Carcinosarcoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.33 ENO2 SYP TUBB3

GO Terms for Ovarian Carcinosarcoma

Sources for Ovarian Carcinosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....